New therapies under development for psoriasis treatment

Current Opinion in Pediatrics

Volumn 25, Issue 4, 2013, Pages 480-487

  García Pérez, Martha Estrella ^a   Stevanovic, Tatjana ^b   Poubelle, Patrice E ^c  

^a Graduated in the Doctorate of Pharmacy   (Mexico)

^b Centre de Recherche sur le Bois   (Mexico)

^c University Laval   (Canada)

Author keywords

antipsoriatic drugs; clinical trials; medications; pharmaceutical development; psoriasis; therapies

Indexed keywords

6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; APREMILAST; BRIAKINUMAB; BRODALUMAB; IXEKIZUMAB; PLACEBO; RUXOLITINIB; SECUKINUMAB; TOFACITINIB;

APOPTOSIS; DRUG SAFETY; HUMAN; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS; REVIEW; T LYMPHOCYTE;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; DERMATOLOGIC AGENTS; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; PSORIASIS;

EID: 84880803402     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e328362c3f6     Document Type: Review

References (27)

1. Parisi R, Symmons DPM, Griffith CEM, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133:377-385.
2. Johnson-Huang LM, Lowes MA, Krueger JG. Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech 2012; 5:423-433.
3. Martin G, Gué rard S, Rosa-Fortin MM, et al. Pathological crosstalk in vitro between T lymphocytes and lesional keratinocytes in psoriasis: necessity of direct cell-to-cell contact. Lab Invest 2012; 92:1058-1070.
4. Menter A, Korman NJ, Craig AE, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol 2011; 65:137-174.
5. Garća-Pé rez ME, Jean J, Pouliot R. Antipsoriatic drug development: challenges and new emerging therapies. Recent Pat Inflamm Allergy Drug Discov 2012; 6:3-21.
6. Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity (PASI): Why do both ? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol 2012; 66:369-375.
7. Fishman P, Bar-Yehuda S, Liang BT, et al. Pharmacological and therapeutic effects of A(3) adenosine receptor agonists. Drug Discov Today 2012; 17:359-366.
8. David M, Akerman L, Ziv M, et al. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol 2012; 26:361-367.
9. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012; 167:668-677.
10. Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol 2012; 67:658-664.
11. Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012; 380:738-746.
12. Bissonnette R, Bolduc C, Maari C, et al. Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial. J Eur Acad Dermatol Venereol 2012; 26:1516-1521.
13. Reich K, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab0 certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol 2012; 167:180-190.
14. Gordon KB, Langley RG, Gottlieb AB, et al. A phase III, randomized controlled trial of the fully human IL12/23 mAb Briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 2012; 132:304-314.
15. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a randomised, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013; 168:412-421.
16. Rich P, Sirgurgeirsson B, Thaci DP, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013; 168:402-411.
17. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody Ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190-1199.
18. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med 2012; 366:1181-1189.
19. O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012; 36:542-550.
20. Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010; 115:3109-3117.
21. Page CP, Spina D. Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Hand Exp Pharmacol 2011; 204:391-414.
22. Moore AR, Willoughby DA. The role of cAMP regulation in controlling inflammation. Clin Exp Immunol 1995; 101:387-389.
23. Kimball A, Gordon K, Langley R, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008; 144:200-207.
24. Krueger JG, Fretzin S, Suarez-Farinas M, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 2012; 130:145-154.
25. Tan X, Feldman SR, Chang J, Balkrishnan R. Topical drug delivery systems in dermatology: a review of patient adherence issues. Expert Opin Drug Deliv 2012; 9:1263-1271.
26. A Service of the US National Institutes of Health. 2013; http://www.clinical trials.gov/ct2/results?termpsoriasisSearchSearch. [Accessed 1 March 2013]
27. Mabuchi T, Chang T, Quinter S, et al. Chemokine receptors in the pathogenesis and therapy of psoriasis. J Dermatol Sci 2012; 65:4-11.